|
Published by: Global Industry Analysts
Published: Oct. 1, 2008 - 73 Pages
Table of Contents
- I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
- A Peek into the Above-Mentioned Procedures
- Plasmapheresis
- Immunoadsorption
- Erythrocytapheresis
- Plateletpheresis
- Leukapheresis
- Photopheresis
- Lipidpheresis
- II. A US MARKET REPORT
- 1. Market Analysis
- A Current & Future Analysis
- A Promising Outlook
- 2. Market Trends
- Apheresis Process Leads to Rise in Platelet Donors
- Therapeutic Apheresis Devices - A Perplexing Market
- Plateletpheresis: The Treatment of Choice for Patients
- Photopheresis Market Growing at a High Rate
- Vendors’ Attitude Hampers Growth Prospects of Therapeutic Apheresis
- Developing New Applications for Therapeutic Apheresis is the Need of the Hour
- CFA - An Effective Way to Pull Up Cold Hemagglutinin Disease
- 3. Competitive Scenario
- Overview
- Technology: The Only Key for Success
- CaridianBCT: The World Leader
- Market Share Trends in the Recent Past
- By Procedures (Revenues)
- Table 1: US Market for Therapeutic Apheresis (2002 & 2005): Percentage Breakdown of Revenues by Company for Gambro BCT, Therakos, Fresenius Hemocare, Kaneka Pharma America Corporation, Baxter Transfusion Therapies, and Others (includes corresponding Graph/Chart)
- By Procedures (Number of Procedures)
- Table 2: US Market for Therapeutic Apheresis (2002 & 2005): Percentage Breakdown of Number of Procedures by Company for Gambro BCT, Therakos, Fresenius HemoCare, Haemonetics, Baxter Transfusion Therapies, and Others (includes corresponding Graph/Chart)
- By Neurology Disorders (Revenues)
- Table 3: US Market for Therapeutic Apheresis in Neurological Disorders (2002 & 2005): Percentage Breakdown of Revenues by Company for Gambro BCT, Fresenius HemoCare, Haemonetics, and Others (includes corresponding Graph/Chart)
- By Neurology Disorders (Number of Procedures)
- Table 4: US Market for Therapeutic Apheresis in Neurological Disorders (2002 & 2005): Percentage Breakdown of Number of Procedures by Company for Gambro BCT, Fresenius HemoCare, Haemonetics, and Others (includes corresponding Graph/Chart)
- By Hematology and Oncology Disorders (Revenues)
- Table 5: US Market for Therapeutic Apheresis in Hematology and Oncology Disorders (2002 & 2005): Percentage Breakdown of Revenues by Company for Gambro BCT, Therakos, Fresenius HemoCare, Baxter Transfusion Therapies, and Others (includes corresponding Graph/Chart)
- By Hematology and Oncology (Number of Procedures)
- Table 6: US Market for Therapeutic Apheresis in Hematology and Oncology Disorders in (2002 & 2005): Percentage Breakdown of Number of Procedures by Company for Gambro BCT, Fresenius HemoCare, Baxter Transfusion Therapies, Therakos, and Others (includes corresponding Graph/Chart)
- 4. Market Overview & Outlook
- Market Drivers
- New Reimbursement Policies Create Growth Opportunities for Therapeutic
- Apheresis
- Increased Industry Consolidation Drives Research
- Development of New Technology
- Research Unveils Novel Applications
- Market Restraints
- Lack of Awareness Restrains Growth
- Therapeutic Apheresis Costs Still a Concern
- Market Challenges
- Development of Inexpensive Apheresis Therapy
- Scarcity of Qualified Donors
- Pediatry: An Untapped Opportunity
- 5. Regulatory Environment
- Regulatory Environment
- 6. Product Overview
- Therapeutic Apheresis: An Introduction
- Overview of Therapeutic Apheresis
- Blood Components
- Apheresis and Therapeutic Apheresis: The Difference
- Therapeutic Apheresis Process
- Duration, Frequency, and Efficiency of Therapeutic Apheresis
- Segregation of Blood Components
- Centrifugation
- Filtration
- History
- Kinds of Therapeutic Apheresis Procedures
- Plasmapheresis
- Erythrocytapheresis
- Plateletpheresis
- Leukapheresis
- Stem Cell Apheresis
- Photopheresis
- Lipidpheresis
- Cytapheresis
- Immunoadsorption
- Rheopheresis
- Therapeutic Apheresis is Remedial for Various Diseases
- 7. Product Trends and Issues
- Therapeutic Plasmapheresis with Fresh Frozen Plasma (FFP) Replacement
- Risks Associated with Therapeutic Apheresis
- Categories of Indications for Therapeutic Apheresis
- Plasma Exchange and Plasmapheresis: The Difference
- Applications of Plasma Exchange
- Chronic Diseases
- Acute Self-Limited Disease
- Emerging Applications
- 8. Technological Developments in Recent Past
- HemoCleanse to Develop Novel Plasmapheresis Device
- Aethlon Develops a New Device to Remove HIV
- Therapeutic Plasmapheresis for Treatment of Autoimmune Diseases
- Occulogix Offers Blood-Filtering Treatment for Macular Degeneration
- 9. Recent Industry Activity
- Gambro to Change Name to CaridianBCT
- Therakos Obtains CE Mark in Europe
- Baxter Divests Transfusion Therapies Business
- SCSG Gets Hold of Fresenius Medical Care Extracorporeal Alliance
- Rheologics Technologies Takes Over Cardiodyne Electronics
- Biotest Obtains Business Unit of Nabi BioPharmaceuticals
- Gambro BCT Receives FDA Clearance for Spectra Optia System
- MedaSorb Receives Rights for Blood Processing
- Fresenius Medical Care Takes Over Renal Care
- Haemonetics Signs Acquisition Agreement with Arryx
- Cerus Receives Rights for INTERCEPT Blood System
- Blood Systems to Implement Gambro BCT 7-day platelets
- 10. Strategic Corporate Developments in Recent Past
- Renal Care Pockets Bay Area Mobile Apheresis Program
- Haemonetics Pacts with FMCEA
- PhereSys and ACGT Ink Consulting Services Pact
- CHF Forges a Service Provider Pact with FMCEA
- Otsuka America Inks a Pact with HemaCare
- Gambro Acquires Ivex
- Fresenius HemoCare Becomes a Part of Fresenius Kabi
- Alpha Therapeutic Sells Assets to Probitas Pharma and Baxter
- Gambro Signs Agreement with The American Red Cross
- Gambro Receives Contract from NBS
- FMC-EA Inks with Allina Hospitals
- Gambro Starts a New Company, Navigant Biotechnologies
- Gambro’s Vista™ Receives Approval from FDA
- Gambro’s New Anticoagulant Solution Receives FDA Approval
- Gambro BCT Receives FDA Clearance for New Filter Tubing Sets Developed by Pall
- Gambro Launches Trima Accel Automated Blood Collection System
- Fresenius HemoCare Acquires PROSORBA® Column from Cypress Bioscience
- Gambro Buys the Assets of Sanguistech
- Haemonetics Inks Purchase Agreement with Alpha Therapeutic Corp
- Gambro Joins Forces with the Walter Reed Army Institute of Research
- Gambro Collaborates with Dendreon for Commercialization of Therapeutic
- Vaccines
- Gambro AB Enters into a Partnership with Sangart
- WakeMed Awards a Contract to HemaCare’s Subsidiary
- HemaCare’s Subsidiary Coral in Agreement with CMH
- BioTransplant Inks an Exclusive Distribution Agreement with Gambro BCT
- Gambro BCT Receives US Patent for its Pathogen Inactivation Technology
- Gambro’s Trima Receives Approval of The Japanese Red Cross Society
- Gambro BCT Test Launches the Vista™ Information System
- HemaCare Enters into a Partnership with LBMMC
- 11. Focus on Select Players
- Baxter Healthcare Corporation
- CaridianBCT, Inc
- Fenwal, Inc
- Fresenius Medical Care North America (FMCNA)
- Haemonetics Corporation
- HemaCare Corporation
- Hospital Clinical Services Group, Inc. (HCSG)
- Therakos, Inc
- 12. Market Perspective
- Table 7: US Recent Past, Current & Future Market Analysis for Therapeutic Apheresis by Procedure - Plasmapheresis, Immunoadsorption, Erythrocytapheresis, Plateletpheresis, Leukapheresis, Photopheresis and Lipidpheresis Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 8: US Long-Term Projections for Therapeutic Apheresis by Procedure - Plasmapheresis, Immunoadsorption, Erythrocytapheresis, Plateletpheresis, Leukapheresis, Photopheresis and Lipidpheresis Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 9: US 10-Year Perspective for Therapeutic Apheresis by Procedure - Percentage Breakdown of Revenues for Plasmapheresis, Immunoadsorption, Erythrocytapheresis, Plateletpheresis, Leukapheresis, Photopheresis and Lipidpheresis Markets Independently Analyzed for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
- Table 10: US Recent Past, Current & Future Market Analysis for Therapeutic Apheresis by End Use - Neurology Disorders, Hematology and Oncology Disorders, Rheumatology Disorders and Other Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 11: US Long-Term Projections for Therapeutic Apheresis by End Use - Neurology Disorders, Hematology and Oncology Disorders, Rheumatology Disorders and Other Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 12: US 10-Year Perspective for Therapeutic Apheresis by End Use - Percentage Breakdown of Revenues for Neurology Disorders, Hematology and Oncology Disorders, Rheumatology Disorders and Other Markets Independently Analyzed for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
- III. COMPETITIVE LANDSCAPE
- Total Companies Profiled: 19 (including Divisions/Subsidiaries - 22)
- Region/Country Players
- The United States 18
- Europe 4
- Germany3
- Rest of Europe 1
-
AbstractThis report analyzes the US market for Therapeutic Apheresis in US$ Thousand. The specific procedures analyzed are Plasmapheresis, Immunoadsorption, Erythrocytapheresis, Plateletpheresis, Leukapheresis, Photopheresis, and Lipidpheresis. The specific end-use segments analyzed are Neurology Disorders, Hematology & Oncology Disorders, Rheumatology Disorders, and Others. The report provides separate comprehensive analytics for the US. Annual forecasts are provided for US region for the period of 2000 through 2015. The report profiles 19 companies including many key and niche players such as Baxter Healthcare Corporation, CaridianBCT, Inc., Fenwal, Inc., Fresenius Medical Care North America, Haemonetics Corporation, HemaCare Corporation, Hospital Clinical Services Group, Inc., and Therakos,, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
Adobe Acrobat Reader 7.0 is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Titles available via "online download" are not affected by this and are still delivered to your reading room immediately.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
